For the first quarter of 2026, analysts expect BioNTech to report a consensus revenue of approximately $207.42 million and an EPS loss of $2.03. With the stock currently trading near $94.97, the average analyst price target of $133.67 suggests a potential upside of over 40% as the company navigates its post-pandemic reset.
Investors are primarily focused on the company’s strategic pivot toward its oncology pipeline as COVID-19 vaccine demand continues to normalize.
The company is expected to highlight progress on its late-stage candidates, particularly the Phase 3 trials for its anti-VEGF/PD-L1 antibody, pumitamig.
Additionally, market participants are looking for updates on the impact of recent manufacturing footprint consolidation aimed at improving operational efficiency and preserving its €16.8 billion cash pile.